Jamie Dananberg, MD is currently the Chief Medical Officer at UNITY Biotechnology. Before joining UNITY, Dananberg served in several roles at Takeda Pharmaceuticals as Executive Vice President, including Head, Cardiovascular and Metabolism Therapeutic Area, and as the Head of both the Therapeutic Areas Group and Experimental/Translational Medicine.
Before joining Takeda, he served in several roles at Eli Lilly & Co., including the Vice President for Translational Medicine and Tailored Therapeutics. Across these roles, Dananberg has brought more than 100 programs from discovery to development, leading and supporting efforts through all phases, including the launches of eight commercial products. He is committed to translating cutting-edge science into actual medicines that positively impact people.
Before joining UNITY, Dananberg practiced medicine in Endocrinology & Metabolism and ran a basic science laboratory at the University of Michigan. He received his BS and MD degrees from Tufts University. His passion is to find insights that arise from the intersection of multiple disciplines. This passion drives his engagement with the national network of Clinical and Translational Science Institutes (CTSI) and his role on the advisory committees for the Indiana CTSI, Chicago CTSI, and MATTER, a biotechnology incubator hub based in Chicago.